Effect of MitoQ versus placebo on clinical outcomes in patients with early septic shock
Phase 3
- Conditions
- Early septic shock.Severe sepsis with septic shockR65.21
- Registration Number
- IRCT20120215009014N499
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Age 18 to 65 years
Premature septic shock
Receive vasopressor for at least 6 and maximum for 24 hours
Exclusion Criteria
Pregnancy or breastfeeding
Treated with other antioxidant and anti-inflammatory drugs
Chronic liver or kidney disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method